Mediscience Tecnology Corp.
Home   About   Investor Relations   News   Intellectual Property   Products   Alliances
  Archive of Press Releases
 

Current

 
 

Archives

 

Dec 17, 2003: the FDA qualified the Mediscience Technology Corp. for both reduced or waived FDA fees for its 2004 medical device 510K market approval submissions

Dec 3, 2003: Mediscience Technology Corp. OTC-MDSC Secures Exclusive World-Wide License to US Molecular Imaging Patent Applications, Expected to Extend Core Technology Additional 17+ Years

Nov. 24, 2003: Breakthrough in Detecting Cancerous Tissue via Stokes Shift Emission Spectroscopy

July 16, 2003: CCNY Receives $6 Million NASA Grant To Enhance Photonics Research

June 4, 2003: Mediscience Technology Announces Formation Of New Subsidiary To Develop Potential Clinical Application For Non-Invasively Diagnosis Of Prostate Cancers

April 28, 2003: Mediscience Technology Appoints Michael Engelhart President and Chief Operating Officer Effective Immediately

March 14, 2003: Mediscience Technology Appoints Michael Engelhart To The Board Of Directors

January 22, 2003: Mediscience Technology Selects THM Group For Commercialization Phase Of Cancer Detection Technology

June 30, 2002: The Research Foundation City University Of New York (Rfcuny) Acquires Major Equity Position In Mediscience Technology Corp.

July 12, 2001: Mediscience Technology Selects Mr. Sidney Braginsky as new President and COO

March. 8, 1999: FDA Approves Phase II in Vivo use of Medisience CD-Scan Optical System as Non-Significant Risk Device in Yale University/Mediscience significant Womens Health Study

March. 24, 1999: Mediscience Cd-Scan Effective in Cornell/New York Medical Barrett's Esophageal Relux Study in Distinguishing Normal Esophageal Tissue From Barrett's or Adenocarcinoma

June 3, 1997: MEDISCIENCE US PATENT ISSUED: Techniques to detect cellular malignancy for PAP SMEAR type samples

March 19, 1997: Mediscience Announces "Incubator" Space on Campus

Jan. 8, 1997: Mediscience Announces FDA "IDE" Approval


THE FDA QUALIFIED THE MEDISCIENCE TECHNOLOGY CORP. FOR BOTH REDUCED OR WAIVED FDA FEES FOR ITS 2004 MEDICAL DEVICE 510K MARKET APPROVAL SUBMISSIONS

CHERRY HILL, N.J., (Dec 17, 2003) - Mediscience Technology Corp. (MTC), (OTCBB:MDSC) of Cherry Hill, New Jersey, a developer of imaging technology for molecular detection of cancer and physiological change, announced: on December 11, 2003 the FDA, after review, qualified the Company under MDUFMA (The Medical Device User Fee and Modernization Act of 2002) allowing both reduced or waived FDA fees for its 2004 medical device 510K market approval submissions." and Company participation in expedited FDA review through FDA clinical inspections conducted independently by third party FDA approved "accredited" persons, directly employed by Mediscience.

President and Chief Operating Officer Michael Engelhart stated, "we are making steady progress in all aspects of our business and continue to expand our leadership in the Optical Biopsy field."

INVESTOR NOTICE:
Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include among other things, the availability of financing, the company's ability to implement its long-range business plan for various applications of its technology; the company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary US regulatory clearances applicable to applications of the company' technology; and management of growth and other risked and uncertainties that may be detailed from time to time in the company's reports filed with the Securities and Exchange Commission. This disclosure is intended to satisfy: SEC Section 6, 6.01 Regulation FD, disclosure and Section 7 and 7.0 as well as all applicable and presently effective Sarbanes-Oxley disclosure requirements under Regulation G.

Top of page

MEDISCIENCE TECHNOLOGY CORP. OTC-MDSC SECURES EXCLUSIVE WORLD-WIDE LICENSE TO US MOLECULAR IMAGING PATENT APPLICATIONS, EXPECTED TO EXTEND CORE TECHNOLOGY ADDITIONAL 17+ YEARS

CHERRY HILL, N.J., (Dec 3, 2003) - Mediscience Technology Corp. (MTC), (OTCBB:MDSC) of Cherry Hill, New Jersey, a developer of imaging technology for molecular detection of cancer and physiological change, announced its contractual acquisition of two exclusive world-wide licenses for US patent applications filed by The Research Foundation City University of New York (RFCUNY). 1. 'Stokes-Shift Fluorescence spectroscopy for detection of disease and physiological state of specimen'and 2. 'Three-dimensional Radiative Transfer Tomography for Turbid Media.'The work results from the Company's continual 10-year+ University research funding relationship. President and Chief Operating Officer Michael Engelhart and CUNY inventor Dr. Robert Alfano state that 'the patents, when issued, would extend the Company's core technology in Optical Biopsy for an additional 17+ years, thus expanding, maintaining and continuing our IP leadership in the Optical Biopsy field.'

NOTE: SEE: Mediscience SEC 8-k filing dated: December 3, 2003

Web Page: medisciencetech.com See (IEEE Journal of selected topics in Quantum Electronics March-April 2003 Vol. 9 Dr. Alfano page 148 and page 189.)

INVESTOR NOTICE: Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include among other things, the availability of financing, the company's ability to implement its long-range business plan for various applications of its technology; the company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary US regulatory clearances applicable to applications of the company'technology; and management of growth and other risked and uncertainties that may be detailed from time to time in the company's reports filed with the Securities and Exchange Commission. This disclosure is intended to satisfy: SEC Section 6, 6.01 Regulation FD, disclosure and Section 7 and 7.0 as well as all applicable and presently effective Sarbanes-Oxley disclosure requirements under Regulation G.

SOURCE: Mediscience Technology Corp. Mediscience Technology Corp., Cherry Hill Michael Engelhart, [email protected] or Peter Katevatis Esq. [email protected]

Top of page

BREAKTHROUGH IN DETECTING CANCEROUS TISSUE VIA STOKES SHIFT EMISSION SPECTROSCOPY

(Nov. 24, 2003) A research team at City College's Institute for Ultrafast Spectroscopy and Lasers (IUSL) headed by Dr. Robert R. Alfano has announced development of a new technique that is much more sensitive than conventional fluorescence Spectroscopy to detect cancerous bio-molecules and structures.

Called "Stokes Shift Emission Spectroscopy," the method grows out of seminal work done at the IUSL for the past two decades. In 1984. IUSL researchers first demonstrated that light could be used to detect cancer from key molecules without removing tissue.

According to Dr. Alfano, "this revolutionary breakthrough will make optical biopsy the new medical frontier for cancer diagnosis and other medical applications."

The emission and absorption of organic molecules in different hosts has been investigated for over fifty years. Information on molecules in different states of matter has been obtained by measuring emission and absorption spectra. For over four decades spectroscopy has played an important role in understanding the fundamental processes that occur in biology, chemistry and solid-slate physics.

Since the discoveries at the IUSL in 1984, spectroscopy has been investigated as a tool to separate cancer, benign and surrounding tissue regions. Typically, tissue is excited at a given wavelength to emit radiation at different wavelengths, which are then used to characterize the tissue. The emission wavelengths serve as "spectral fingerprints" for changes in the structure and content of various proteins in the tissue. "For organic molecules, typically, the peaks of absorption and emission occur at different wavelengths," Dr. Alfano said, "and the emission band occurs at lower energy than the excitation band."

This difference between the emission and absorption peaks, known as the Stokes Shift, depends in part on the polarity of the host environment surrounding the emitting organic molecule. The new detection method developed at the IUSL combines the fluorescence and absorption spectra of molecules in tissue and is known as "Stokes Shift Emission Spectroscopy."

"The excitation and emission wavelengths are scanned simultaneously with a fixed value between the excitation and emission wavelengths," according to Dr. Alfano. "This approach is much more sensitive than ordinary fluorescence spectroscopy and has delivered dramatically improved results in detecting changes in native bio-molecules. It offers great promise, therefore, in detecting cancerous, pre-cancerous and normal tissues."

When comparing the effectiveness of the Stokes Shift Emission Spectroscopy (SS) method with conventional fluorescence spectroscopy it is clear that this method is a more selective and a more effective means of distinguishing cancerous from normal tissue.

Dr. Alfano called this as a "giant step forward for scientists at the IUSL," who pioneered using optical spectroscopy to diagnose cancer without removing tissue. The latest advance has the potential to detect tumors involving the breast, cervix, gastrointestinal tract, head and neck, prostate, liver, brain, kidney, bladder and other organs.

This work has been supported, in part, by Mediscience Technology Corp. and funds from organized research at The City University of New York.

Top of page

CCNY RECEIVES $6 MILLION NASA GRANT TO ENHANCE PHOTONICS RESEARCH

With support from a five-year $6 million University Research Center Program grant from the National Aeronautics and Space Administration (NASA), City College has established a Center for Optical Sensing and Imaging (COSI) designed to provide benefits in the technical, scientific and social fields.

The Center’s primary goal is to develop improved sensing and imaging instruments and techniques that will contribute to NASA research and future NASA missions. It will also attract and train underrepresented minority students in related science and engineering disciplines.

COSI is headed by the renowned Dr. Robert R. Alfano, Distinguished Professor of Science and Engineering at CCNY, and Dr. Sam Ahmed, Herbert G. Kayser Professor of Electrical Engineering.

“The high quality research, economic and social impacts that this program will produce will be of significant value to the people of New York State and could aid in the recovery of New York City,” said Dr. Alfano, who is also heads CCNY’s Institute for Ultrafast Spectroscopy and Lasers, and directs New York State’s CUNY Center for Advanced Technology in Ultrafast Photonics and Applications.

Dr. Alfano said COSI promises many tangible benefits, including increased educational opportunities for minority students; a better-trained technical workforce; discoveries that improve lives; and commercial innovations to help local businesses improve efficiency and stay competitive.

The new Center will enable CCNY to expand its efforts in training and graduating minority US students in the sciences and engineering by establishing a strong research, education and outreach program to recruit, retain, mentor and train students.

CCNY is an important Other Minority University (OMU) and Hispanic Serving Institution (HSI) with a strong record of training and educating talented students from underrepresented ethnic groups for careers in the sciences and engineering.

“The program will train a minimum of 16 graduate and 10 under-graduate students annually, and will also institute a vigorous K-12 science education program,” said Dr. Manuel Zevallos, COSI’s Administrative and Technical Coordinator.

The scientific and technological objectives of COSI include development of optical techniques and instruments (for both in-situ and ground- and satellite-based remote applications) for:

  • Development of lasers and detectors for use in remote sensing and optical communications;
  • Imaging targets and transmitting optical signal through clouds, fog, ice, and rain;
  • Detection of vegetation and land cover and measurement of the temperature of ocean waters;
  • Atmospheric and ocean monitoring;
  • Sensing microorganisms (e.g., bacteria) in the environment.

The Center brings together the teams of two major existing NASA institutional programs at City College: NASA IRA (Tunable Solid State Lasers) of the Institute for Ultrafast Spectroscopy and Lasers (IUSL), and NASA PAIR (Remote Sensing and Environmental/Climat Studies) of the International Center for Environmental Resources and Development (ICERD), to form a complementary multi-disciplinary University Research Center.

CCNY also is home to the New York State Center for Advanced Technology in Ultrafast Photonics and the NOAA Cooperative Center for Remote Sensing Science and Technology.

Other CCNY researchers participating in the Center include Dr. Swapan Gayen, Dr. Vladimir Petricevic, Dr. Alvin Katz, Dr. Wubao Wang, Dr. Mikhail Sharonov and Dr. Shengkun Zhang (Physics); Dr. Barry Gross, Dr. Fred Moshary and Dr. Ping-Pei Ho (Electrical Engineering); Dr. Jeffrey Steiner (Earth and Atmospheric Sciences), and Dr. Reza Khanbilvardi (Civil Engineering). Dr. Charles B. Watkins, Herbert G. Kayser Professor of Mechanical Engineering, is COSI’s Educational and Outreach Coordinator.

The CCNY researchers will maintain their close collaboration with NASA scientists and engineers, as well as with partners from industry such as Lockheed Martin, Raytheon, and GER Inc. to keep the research focused on NASA and real-world needs, and to facilitate transfer of dual use technology to the marketplace.

Dr. Alfano said that COSI would enjoy strong support from CCNY and the City University of New York (CUNY) and was a welcome new component to strengthen CUNY’s Photonics Initiative.

Top of page

MEDISCIENCE TECHNOLOGY ANNOUNCES FORMATION OF NEW SUBSIDIARY TO DEVELOP POTENTIAL CLINICAL APPLICATION FOR NON-INVASIVELY DIAGNOSIS OF PROSTATE CANCERS.

Cherry Hill, NJ (June 4, 2003) - Mediscience Technology (OTCBB - "MDSC"), a medical diagnostics device company, is pleased to announce the formation of "PROSCREEN, LLC". The Company, a wholly owned subsidiary of Mediscience Technology has a potential clinical application for non-invasively diagnosing prostate cancers without removing prostate tissues.

Prostate cancer has a high incidence and mortality rate for men. Every year, nearly 180,000 new prostate cancer cases are diagnosed, and about 37,000 deaths annually are caused by prostate cancers in U.S. Current techniques for detection of prostate cancers have limited accuracy. The regular methods for monitoring prostate cancers are the prostate specific antigen (PSA) blood test and a digital rectal examination (DRE). When the PSA level is elevated or the DRE abnormal, there is a one-in-three chance that cancer is present. This can only be confirmed by a needle biopsy of the prostate. In the biopsy, a number of cores of prostate tissue are taken with a thin needle guided into selected regions of the prostate with an ultrasound probe. Since the ultrasound imaging has poor spatial resolution and contrast, and needle biopsy is invasive, better methods are needed to develop high resolution and noninvasive techniques to detect early small prostate cancers.

Michael Engelhart, President and COO of Mediscience Technology said, "The prospects for this project are very exciting and can potentially enhance prostate diagnosis and thereby create more favorable patient outcomes. We are evaluating various methods to determine the best imaging technique. After we select the best approach, we will develop a prototype spectral polarization imaging unit with an optical fiber probe for prostate cancer detection, and engage in performing clinical tests."

Engelhart added, "Our initial project will include three phases. In phase 1, we will complete the evaluation of the imaging technique to select the best imaging method for the device design. In phase 2, we will design the device, purchase the parts, and build a prototype spectral polarization imaging unit with an optical fiber probe. In phase 3, we will assist in performing clinical test with a medical collaborator such as Hackensack University Medical Center and modify the unit based on the clinical results."

Peter Katevatis, Chairman/CEO "The formation of "PROSCREEN, LLC" is consistent with Mediscience's overall strategy of rolling out the company's constellation model; the first of which was Photonics for Women's Oncology, LLC." We continue to build our IP and exiting product base directly from our on-going research relationship at CUNY's INSTITUTE FOR LASERS AND ULTRA-FAST SPECTROSCOPY with the dedication of its Director, Dr. Robert Alfano, and other associated medical and engineering staff.

About Mediscience Technology---Mediscience Technology Corp. is engaged in the design and development of diagnostic medical devices that detect cancer using light induced native tissue fluorescence spectroscopy to distinguish between malignant normal, dysplastic or benign tissue.

This press release contains forward-looking statements involving risks and uncertainties that may cause actual results to differ materially from those indicated due to a number of factors. The Company's plans and objectives are based on assumptions involving judgments with respect to future economic, competitive, and regulatory and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of the Company. Therefore, there can be no assurance that the forward-looking statement will prove to be accurate. The Company's documents filed with the SEC identify important factors that may cause the actual results to differ materially from those indicated by the forward-looking statements. This disclosure is intended to satisfy: SEC Section 6, 6.01 Regulation FD, disclosure and Section 7 and 7.0 as well as all applicable and presently effective Sarbanes-Oxley disclosure requirements under Regulation G.

Reference:

Contact Persons:
 Pres. COO
Michael Engelhart
Chairman/CEO
Peter Katevatis Esq.
(201) 818 0050(856) 428 7952
[email protected][email protected].

Top of page

MEDISCIENCE TECHNOLOGY APPOINTS MICHAEL ENGELHART PRESIDENT AND CHIEF OPERATING OFFICER EFFECTIVE IMMEDIATELY.

Cherry Hill, NJ (April 28, 2003) - Mediscience Technology (OTCBB - "MDSC"), a medical diagnostics device company, is pleased to announce that effective April 26, 2003, Michael Engelhart has been appointed President and Chief Operating Officer Mr. Engelhart, 40, focus will be to evaluate and create alternative strategies in an effort too maximize shareholder value and create the needed funding mechanism. Effective April 26, 2003 Mr. Sidney Braginsky, former President COO and the Registrant agreed to the termination of his July 9, 2001 agreement effective retroactively as of July 9, 2001. He will continue as a Board member providing consulting services to the Board and President COO Michael Engelhart as needed.

"We are pleased to welcome someone with Michael's operational experience. Mediscience continued progress will require a continued focus on operational excellence as well as successful corporate development activities. Michael brings a fresh perspective and a wealth of experience in ensuring that we make the best use of our capital," said Peter Katevatis, Esq., Chairman and CEO.

"I appreciate the opportunity presented and confidence of the Mediscience Board of Directors and Peter Katevatis, Chairman and CEO in what could be a very important set of commercial ventures aimed at early cancer detection. We are pleased with the pace of our continued development of the cervical cancer detection device, where we have completed a final prototype. We are encouraged by the early results of our capital raising and business development activities that support and expedite the path to commercialization." Said Michael Engelhart, President and COO of Mediscience.

About Mediscience Technology---Mediscience Technology Corp. is engaged in the design and development of diagnostic medical devices that detect cancer using light induced native tissue fluorescence spectroscopy to distinguish between malignant normal, dysplastic or benign tissue.

This press release contains forward-looking statements involving risks and uncertainties that may cause actual results to differ materially from those indicated due to a number of factors. The Company's plans and objectives are based on assumptions involving judgments with respect to future economic, competitive, and regulatory and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of the Company. Therefore, there can be no assurance that the forward-looking statement will prove to be accurate. The Company's documents filed with the SEC identify important factors that may cause the actual results to differ materially from those indicated by the forward-looking statements. This disclosure is intended to satisfy: SEC Section 6, 6.01 Regulation FD, disclosure and Section 7 and 7.0 as well as all applicable and presently effective Sarbanes-Oxley disclosure requirements under Regulation G.

Reference 8-K EDGAR filing April 28,2003/ Company's website at medisciencetech.com/forms/8-K_4_29_03.htm

Contact Persons: Pres. COO Michael Engelhart (201) 818 0050 [email protected] : Mediscience Technology Corp. Peter Katevatis Esq. Chairman/CEO (856) 428 7952 [email protected].

Top of page

MEDISCIENCE TECHNOLOGY APPOINTS MICHAEL ENGELHART TO THE BOARD OF DIRECTORS

Cherry Hill, NJ (March 14, 2003) - Mediscience Technology (OTCBB - "MDSC"), a medical diagnostics device company, is pleased to announce that effective March 13, 2003 Michael Engelhart has been appointed to the Board of Directors.

Mr. Engelhart, 40, is the CEO of THM Group, LLC, a New Jersey based strategic consulting organization. THM Group was retained by Mediscience to evaluate and create alternative strategies in an effort too maximize shareholder value.

"We are pleased to add to our board someone with Michael's operational experience in running strategic and corporate development functions at both large and small diversified companies. Mediscience continued progress will require a continued focus on operational excellence as well as successful corporate development activities. Michael will bring a fresh perspective and a wealth of experience in ensuring that we make the best use of our capital," said Peter Katevatis, Esq., Chairman and CEO of Mediscience.

About Mediscience Technology

Mediscience Technology Corp. is engaged in the design and development of diagnostic medical devices that detect cancer using light induced native tissue fluorescence spectroscopy to distinguish between malignant and normal or benign tissue

This press release contains forward-looking statements involving risks and uncertainties that may cause actual results to differ materially from those indicated due to a number of factors. The Company's plans and objectives are based on assumptions involving judgments with respect to future economic, competitive, and regulatory and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of the Company. Therefore, there can be no assurance that the forward-looking statement will prove to be accurate. The Company's documents filed with the SEC identify important factors that may cause the actual results to differ materially from those indicated by the forward-looking statements.

Contact Persons: THMGROUP LLC Michael Engelhart (201) 818 0050 [email protected]: Mediscience Technology Corp. Peter Katevatis Esq. Chairman/CEO (856) 428 7952 [email protected]

For more information, visit the Company's website at medisciencetech.com.

Top of page

MEDISCIENCE TECHNOLOGY SELECTS THM GROUP FOR COMMERCIALIZATION PHASE OF CANCER DETECTION TECHNOLOGY

For Immediate Release

Cherry Hill, NJ (January 22, 2003) - Mediscience Technology (OTCBB - "MDSC") of Cherry Hill, New Jersey, a company developing technology for molecular detection of cancer and physiological change, announced the appointment of THM Group, LLC as exclusive advisor to explore options for the company to commercialize its technology.

Peter Katevatis Esq., Chairman said" Mediscience has steadfastly developed its science to the conclusion of the research phase and now with the expert participation and assistance of THM Group expects to timely commercialize its paradigm platform technology.

Michael Engelhart, Chief Executive Officer of THM Group said, "We are looking forward to putting all of THM's capabilities behind the patent platform and prototype equipment of these exciting devices that we believe will significantly improve upon early cancer detection. We are pleased that Mediscience has entrusted us to provide options in an effort to maximize the return on their investment."

About Mediscience Technology

Mediscience Technology Corp. is engaged in the design and development of diagnostic medical devices that detect cancer- using light induced native tissue fluorescence spectroscopy to distinguish between malignant and normal or benign tissue.
medisciencetech.com

About THM Group

THM Group is focused on raising capital, carrying out project feasibility and business development projects for going businesses of private and public companies, and acting as an officer in early stage or troubled companies

This press release contains forward-looking statements involving risks and uncertainties that may cause actual results to differ materially from those indicated due to a number of factors. The Company's plans and objectives are based on assumptions involving judgments with respect to future economic, competitive, and regulatory and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of the Company. Therefore, there can be no assurance that the forward-looking statement will prove to be accurate. The Company's documents filed with the SEC identify important factors that may cause the actual results to differ materially from those indicated by the forward-looking statements.

Contact Persons: THMGROUP LLC Michael Engelhart (201) 818 0050 [email protected]: Mediscience Technology Corp. Peter Katevatis Esq. Chairman/CEO (856) 428 7952 [email protected]

SEC 8-k filed 1/22,2003, and posted on Company web medisciencetech.com per Sarbanes-Oxley Full Disclosure requirements

Top of page

THE RESEARCH FOUNDATION CITY UNIVERSITY OF NEW YORK (RFCUNY) ACQUIRES MAJOR EQUITY POSITION IN MEDISCIENCE TECHNOLOGY CORP.

Cherry Hill, NJ (June 30, 2002) - Mediscience Technology Corp. (MTC), (OTCBB- "MDSC") of Cherry Hill New Jersey, a developer of imaging technology for molecular detection of cancer and physiological change, announced its revised contract with The Research Foundation City University of New York (RFCUNY) effective May 31, 2002 The agreement, erases all (MTC) debt, reduces all company royalty rate obligations from 5% to 3.25% and affirms ownership and/or exclusive license of all Medical Applications embodied in (MTC's) patent list, in exchange for consideration to (RFCUNY) of:

  1. Cash payment of $85,045.
  2. Issuance to (RFCUNY) of 283,228 SEC 144 shares.
  3. Issuance of a five (5) year Share Warrant to (RFCUNY) providing the right to purchase six hundred thousand (600,000) SEC 144 shares at one dollar ($1.00) per share.

(RFCUNY) now has a total 4% beneficial interest in Mediscience common Rule 144 shares, exercisable as Share Warrants at one dollar ($1.00) per share for a total of One Million one hundred thousand (1,100,000) shares.

Effective May 31, 2002 (MTC) fully funded its new agreement-- Term: July 1, 2002 to June 30, 2003, with "The Institute for Ultra fast Spectroscopy and Lasers Center for Ultrafast Photonics and Mediphotonics Laboratory of City University of New York". This 10-year+ relationship provides continual technical and research assistance to in support of existing and anticipated clinical trials in the United States and India.

NOTE: SEE: Mediscience SEC/EDGAR 8-k filing 6/1/2002
            Web Page: medisciencetech.com

INVESTOR NOTICE:

Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include among other things, the availability of financing, the company's ability to implement its long-range business plan for various applications of its technology; the company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the company' technology; and management of growth and other risked and uncertainties that may be detailed from time to time in the company's reports filed with the Securities and Exchange Commission.

Top of page

MEDISCIENCE TECHNOLOGY SELECTS MR. SIDNEY BRAGINSKY AS NEW PRESIDENT AND COO

Cherry Hill, NJ -- July 12, 2001 (SEC-EDGAR filing 10-QSB)-- Effective July 9th 2001 Peter Katevatis, Esq. Chairman CEO on behalf of the Company entered into an employment relationship with Mr. Sidney Braginsky as the new President and COO. Mr. Braginsky was formerly with OLYMPUS OPTICAL LTD for 27 years most recently as President CEO of OLYMPUS AMERICA, Inc., the Olympus US subsidiary. OLYMPUS LTD. is a multinational corporation headquartered in Tokyo Japan and a world leader in microscopes, endoscopes, automatic blood and fluid chemistry analyzers measuring research, industrial and consumer products.

The Company will seek investment and/or corporate partners to support the funding of a joint effort between itself, Sarnoff Corporation, and the Mediphotonics Laboratory of the City University of New York to develop and commercialize an advanced, second generation version of its proprietary two-dimensional fluorescence imaging system for early cancer detection.

Mr. Braginsky is a present board member of, NOVEN Pharmaceuticals, REDOX Pharmaceuticals, ELECTRO-OPTICAL SYSTEMS, Inc., ESTEK CARDIOLOGY, Chairman of Double D Venture Funds LLC and Chairman of the Board of City College of New York's Robert Chambers Laboratory.

Top of page

MEDISCIENCE CD-SCAN EFFECTIVE IN CORNELL/NEW YORK MEDICAL BARRETT'S ESOPHAGEAL RELUX STUDY IN DISTINGUISHING NORMAL ESOPHAGEAL TISSUE FROM BARRETT'S OR ADENOCARCINOMA

Cherry Hill, N.J., March 24, 1999 Mediscience Technology Corp. (OTC Bulletin Board: MDSC), pioneer developer and designer of non- invasive photonic technology used in medical diagnostic instruments that detect cancer/molecular changes based upon differentiations in the amount of light re-emitted from malignant and benign tissue reports findings published January 23-29, 1999 at the SPIE Optical Tomography and Spectroscopy of Tissue lll Conference by Principle Investigator Paul M. Basuk MD, New York Hospital-Cornell Medical Center together with researchers Dr. Alvin Katz and Dr. Howard Savage from the New York State Center of AdvancedTechnology in Ultra Fast Photonics, (CUNY) in a Mediscience supported "Investigation of Barrett's esophagus by ultraviolet and visible fluorescence emission and excitation spectroscopy." (Optical Biopsy, Section-presentation talk No. 3597-61).

Paul M. Basuk MD used the Mediscience CD-scan device on excised human gastrointestinal tissue to monitor patients with Barrett's esophagus, (a pre-malignant condition characterized by symptomatic gastroesophageal reflux), and concluded that "his work shows UV emission measurements can effectively distinguish normal esophageal tissue from Barrett's or adenocarcinoma. Further preliminary data also indicates that the combination of UV emission and excitation measurements can potentially separate non-dysplasia Barrett's from dysplasia and cancer as well as from normal tissues." On March 19, 1999 The New England Journal of Medicine Vol.340, No.11 reported on a study of "Symptomatic Gastrosophageal Reflux as a risk factor for esophageal Adinocarcinoma" concluding that there is a strong and probable causal relation between gastroesophageal reflux and esophageal adenocarcinoma.

Esophageal adenocarcinoma is treatable but rarely curable, mortality is high and successful treatment depends on early detection. Mediscience optical detection of dysplasia, intergrated into an endoscopic examination, can significantly improve the accuracy of biopsy sight selection, thereby increasing the likelihood of early detection of malignancy, and reducing the number of random negative biopsies during an upper gastrointestinal tract endoscopic examination.

Mediscience experience in excitation of important tissue molecules shows improved diagnostic accuracy in the range of 80 to 90% with measurement time a few seconds (real-time). The greatest increase in the incidence of this disease is seen in males, particularly over the age of 60, with the major risk factors of alcohol and tobacco. Since Barrett's esophagus appears to be a predisposing factor for cancer, screening such high risk patients for the development of adenocarcinoma would be appropriate.

Mediscience propriety technology predictably can retro-fit existing and future endoscopes for this and other diagnostic purposes creating intelligent instrumentation for the physician - a significant world-wide market opportunity.

Mediscience has been conducting research in this field since 1988 and presently is conducting two FDA approved studies. "Yale/Mediscience "in-vivo" Phase ll womens health related non-significant risk device was approved January 25, 1999" and FDA approved Phase ll "in-vivo" study for Oral Aerodigestive cancer, approved after successfully completed the Phase I study at Memorial Sloan Kettering New York City. Under the direction of Dr. Stimson Schantz with NCI support. The company intends to additionally file with the FDA in furtherance of Dr. Basuk's work. Both Dr. Basuk's and Dr. Schantz's work concern alcohol and tobacco related cancer.

Mediscience owns exclusive rights to 17 patents in the field of Bio-Optics. Its CD-Scan and other prototype devices are based on its patented optical fluorescence. spectroscopy technology.

With the current medical validation and concern regarding gastroesophageal reflux, there exists a major market opportunity in the United States for Mediscience Technology. In the far east (China, Japan, East and South Africa) the disease is almost epidemic, (130 cases per 100,000 population), indicating mass screening as essential for those and other communities.

Certain matters discussed in this announcement contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934 that involve material risks to, and uncertainties in the company's business which may cause actual results to differ materially from those anticipated by the statements made herein.

Contacts:Peter Katevatis Pres.    Dr. Paul M. Basuk
609-428-7952Gastrointestinal Endoscopy
New York Hospital, Cornell Med Ctr.
212-745-4901

Top of page

FDA APPROVES PHASE II IN VIVO USE OF MEDISIENCE CD-SCAN OPTICAL SYSTEM AS NON-SIGNIFICANT RISK DEVICE IN YALE UNIVERSITY/MEDISCIENCE SIGNIFICANT WOMENS HEALTH STUDY. (March 8, 1999)

CHERRY HILL, NJ, March 8, 1999 - Peter Katevatis announced that Mediscience Technology Corp. (OTC.MDSC), developer and designer of non-invasive photonic technology used in medical diagnostic instruments that detect cancer/molecular changes based upon differentiations in the amount of light re-emitted from malignant and benign tissue, has entered into are search agreement with Yale University under which Frederick Naftolin Chairman OBGYN Yale University Dept. of Obstetrics and gynecology as the principle Investigator, will investigate the biological basis of fluorescence as applied to medically significant OBGYN Health issues using the Mediscience CD-Scan with FDA approval (Jan. 25, 1999) as a non-significant risk device for the proposed in Vivo Phase II Clinical investigation. In particular, the autofluorescence from specific areas will be examined to establish non-invasive diagnostic information of value in specificity and analysis to the OBGYN practitioner. The FDA approved clinical trial will obtain in Vivo and statistics which will lead o a broader multi-site effort.

Mediscience has been conducting research in this field since 1988 and in a separate effort successfully completed a FDA approved phase I clinical evaluation with CD-Scan in human Patients under an NCI supported study of Aerodigesrtive (tobacco related) Cancer at Memorial Sloan-Kettering Hospital, New York City and is presently positioned to enter FDA Approved Phase II and Phase II (multi-sites) towards pre-market approval under the continued direction of principle investigator Stimson Schantz MD.

The potential annual market for clerical cancer and related woman health issues is approximately $1.25 Billion. Preliminary results of the Yale/Mediscience FDA approved in Vivo clinical trial are expected during 1999.

Mediscience, a leader in this field, owns exclusive rights to 17 pioneering and early seminal patents in the field of Optical Biopsy and Optical Mammogrophy. iTS CD-Scan and other prototype devices are based on its patented optical fluorescence spectroscopy technology.

Certain matters discussed in this announcement contain forward-looking statements within the meaning of section 27A of the Securities act of 1933 and Section 21E of the Securities Act of 1934 that involve material; risks to, and uncertainties in the company's business which may cause actual results to differ materially from those anticipated by the statement made herein.



Top of page

MEDISCIENCE US PATENT ISSUED:  Techniques to detect cellular malignancy for PAP SMEAR type samples(June 3, 1997)

CHERRY HILL, NJ, July 1 1997 - Peter Katevatis, President and CEO of Mediscience Technology Corp. (MDSC, OTC Bulletin Board), announced that MTC has acquired the rights to a new patent for a technique to detect cellular malignancy. This technique can be used to screen in vitro cell smears.

Using the fundamental principle known as extrinsic fluorescence spectroscopy, it is possible to distinguish normal cells from malignant cells that have been treated with a fluorescent dye. The fluorescent dye is preferably absorbed by malignant cells resulting in an enhanced discrimination fluorescent signature compared to that from normal cells. The technique can he deployed in an automated system to map the distribution of malignant cells, such as found in Pap smear-type samples.

The inventors of the patent (#5,635,402: June. 3, 1997) - Robert R. Alfano, Cheng. H. Liu, Wei L. She, and Yury Budanski -are associated with the Mediphotonics Laboratory and the Institute for ultrafast Spectroscopy and Lasers at City College of New York. Alfano and coworkers hold patents for many cancer diagnostic and imaging techniques.

MediScience is a technology development corporation specializing in medical diagnostic applications that use lasers and optical imaging MTC is receptive to inquiries on licensing and joint ventures on this and other technologies it owns.

Except for the historical information contained herein, the matters set forth in this news release arc forward-looking statements that are dependent on certain risks and uncertainties including such factors, among others, as the Company's ability to continuously satisfy the FDA's requirements for safety of its devices, its ability to raise sufficient capital to conduct the human clinical trials necessary to ultimately prove the safety of its devices and its ability to sell its devices to health care providers if it is successful in completing their development.

Top of page

MEDISCIENCE ANNOUNCES "INCUBATOR" SPACE ON CAMPUS

Cherry Hill, New Jersey, (March 19, 1997). Mediscience Technology Corp. (OTC-MDSC) announced today that it has executed a lease agreement with City College of New York (CCNY) providing space in an "incubator" for transfer of the technology from Metiphotonocs Laboratory (MPL) at CCNY to MDSC. This lease is the first step in producing units. Prototypes of the Company's diagnostic instruments will be designed and assembled by MPL staff working in concert with personnel from an engineering design firm that has been retained by the company. These units will be used in clinical evaluation. Know-how will be transferred to the company for its manufacturing stages for well defined endoscopic based devices for the gastroenterology, gynecology and urology markets.

The next phase for MDSC will be to create a pilot facility in which several diagnostic instruments will be assembled. The location of the incubator and pilot facility affords Mediscience the advantage of having its design engineers work side-by-side with the MPL research scientists and all within close proximity to the medical institutions in the New York are where the instruments are to be clinically tested.

The Company plans to manufacture and assemble its medical device products on relationship with contract manufactures and/or business partners in the medical device field when the devices are commercialized. Contract manufacturer(s) will be selected from a list of highly qualified companies who are familiar with the regulatory requirements of the FDA for the manufacture of medical devices, who are registered with and in good standing with the FDA.

Except for the historical information contained herein, the matters set forth in this news release are forward-looking statements that are independent in certain risks and uncertainties including such factors, among others, as the Company's ability to continuously satisfy the FDA's requirements for safety of its devices, its ability to sell its devices to health care providers if it is successful in completing their development.

Mediscience owns exclusive rights to 15 patents in the field of Bio-Medical Optics. Its CD Scan and CD Ratiometer prototype medical devices are based on its patented optical fluorescence spectroscopy technology which can distinguish between normal and cancerous tissue in-vivo (in the body) in a non-invasive manner by optically scanning the surface of suspect tissue with a fiberoptic probe and comparing the resulting fluorescence spectral response to a similar scan of healthy tissue.

Top of page

MEDISCIENCE ANNOUNCES FDA "IDE" APPROVAL(Jan. 8, 1997)

Cherry Hill, New Jersey. January 8, 1997 - Medisciencc Technology Corp. (OTC-MDSC) announced today that it received FDA approval of its Investigational Device Exemption to initiate phase II clinical trials with its CD Scan medical device for early stage detection of cancer. The specific protocol approved for study with this IDE is a double blind, randomized study of patients with oral leukoplakia. a pre-cancerous condition in the mouth. Half the patients will be treated with the drug; l3-cis retinoic acid and the other half with placebo and the entire study population will he followed up routinely during the study period with the CD Scan and via other techniques to assess changes of the patient's medical condition. The Company hopes to demonstrate that its CD Scan device and its Tissue Fluorescence technology can provide in vivo (in the body) results, non-invasively, comparable to those derviced from excisional biopsy. If successful in this trial, Mediscience contemplates expand-ing the study population to gather sufficient data to support premarket approval. This human clinical study will be conducted at the Sloan Kettering Cancer Research Center in New York City. The study co-sponsors are Mediscience and the National Cancer Institute.

"The Company has made tremendous progress in the last year", according to Peter Katevatis, Chairman of Mediscience. "Approval of this IDE demonstrates that Mediscience has now developed the know-how and necessary infrastructure to deal effectively with the FDA on matters of importance both to the Company and the FDA."

Mediscience is already preparing its next IDE submission which is targeted at a gastrointestinal tract pre-cancerous condition that will employ both the Company's CD Scan device and its second-generation device, CD Ratiometer. The Company hopes to be in a position to file for IDE approval to conduct that study later this quarter. In this planned clinical trial the Company's objective will be to demonstrate the technical and clinical feasibility of non-invasive detection of pre-cancerous conditions of the esophagus at an early enough stage where preventive therapy is highly effective before proceeding into the "pivotal" clin-ical trial to support premarket approval of its device for that application.

Except for historical Information contained herein, the matters set forth in this news release are forward-looking statements that are dependent on certain risks and uncertainties including such factors, among others, as the Company's ability to continuously satisfy the FDA's requirements for safety of its devices. its ability to raise sufficient capital to conduct the human clinical trials necessary to ultimately prove the safety and effectiveness of its devices and its ability to sell its devices to health care providers if it is successful in completing their development.

Mediscience owns exclusive rights to IS patents in the field of Bio-Medical Optics. Its CD Scan and CD Ratiometer medical devices alt based on its patented Tissue Fluorescence technology which can distinguish between normal and cancerous tissue in vivo (in the body) in a non-invasive manner by optically scanning the surface of suspect tissue with a fiberoptic probe and comparing the resulting fluorescence spectrum to a similar scan of healthy tissue.

Top of page

 
     Copyright © 2004 Mediscience Technology Corp. Contact Us